ALFA FinderNSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹975.55
- Market cap
- ₹2,171 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 50.6×Sector 43.0×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Other annual general meeting announcements
All →Generic Engineering Construction and Projects Annual General Meeting
Generic Engineering's 32nd AGM is scheduled for November 30, 2026 via VC/OAVM. Agenda includes FY26 financial statements, director reappointment and related-party transactions approval.
Kirloskar Industries Annual General Meeting
Kirloskar Industries forwarded its subsidiary KFIL's postal ballot scrutinizer report. Shareholders passed resolutions appointing Ajay Shriram Patil as a director and as Joint Managing Director.
Umiya Tubes Annual General Meeting
Umiya Tubes submitted voting results and the scrutinizer report for its postal ballot ending 7 November 2026. Resolution 1, alteration of the name clause, passed as a special resolution with 100% of votes cast in favour.
Prime Focus Annual General Meeting
Prime Focus Limited's EOGM held on 7 November 2026 passed all resolutions with requisite majority. Resolutions cover cessation of control over Brahma AI Holdings and related party transactions involving its subsidiaries.
Jagsonpal Services Annual General Meeting
Jagsonpal Services shareholders approved an asset-acquisition business transfer agreement with Elanistech via postal ballot. A name-change certificate was also noted.
Vineet Laboratories Annual General Meeting
Vineet Laboratories has circulated notice of its 10th AGM, scheduled for 30 November 2026 via video conferencing. The filing attaches the FY 2025-26 annual report.